PMID- 36606059
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 9
DP  - 2022
TI  - EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent 
      organ damage in systemic lupus erythematosus.
PG  - 1092325
LID - 10.3389/fmed.2022.1092325 [doi]
LID - 1092325
AB  - OBJECTIVES: To investigate whether self-reported EQ-5D full health state (FHS) 
      after therapeutic intervention for active systemic lupus erythematosus (SLE) is 
      associated with a reduced risk to accrue organ damage. In a separate analysis, we 
      sought to investigate associations between experience of "no problems" in each 
      one of the five dimensions of EQ-5D and the risk to accrue damage. METHODS: Data 
      from the open-label extension periods of the BLISS-52 and BLISS-76 trials of 
      belimumab in SLE (NCT00724867; NCT00712933) were used (N = 973). FHS was defined 
      as an experience of "no problems" in all five EQ-5D dimensions. Organ damage was 
      assessed annually using the Systemic Lupus International Collaborating Clinics 
      (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI). Associations 
      between the three-level version of the EQ-5D (EQ-5D-3L) responses at open-label 
      baseline and the first documented increase in organ damage were investigated 
      using Cox regression accounting for age, sex, ancestry, SDI at baseline, and 
      background therapy, and associations with SDI items were investigated using phi 
      (phi) correlation analyses. RESULTS: A total of 147 patients (15.1%) accrued organ 
      damage during follow-up, with the first increase in their SDI score occurring 
      after a mean time of 29.1 +/- 19.6 months. Lower proportions of FHS respondents 
      accrued damage over a course of up to 7.9 years of open-label follow-up compared 
      with no FHS respondents (p = 0.004; derived from the logrank test). FHS was 
      associated with a reduced hazard to accrue subsequent organ damage (HR: 0.60; 95% 
      CI: 0.38-0.96; p = 0.033) after adjustments, as was experience of "no problems" 
      in mobility (HR: 0.61; 95% CI: 0.43-0.87; p = 0.006). "No problems" in mobility 
      was negatively correlated with musculoskeletal damage accrual (phi = -0.08; p = 
      0.008) and associated with a lower hazard to accrue musculoskeletal damage in Cox 
      regression analysis (HR: 0.38; 95% CI: 0.19-0.76; p = 0.006). CONCLUSION: 
      Experience of EQ-5D-3L FHS and "no problems" in mobility after therapeutic 
      intervention heralded reduced hazard to accrue subsequent organ damage, 
      especially musculoskeletal damage, suggesting that optimisation of these 
      health-related quality of life aspects constitutes a clinically relevant 
      treatment target in patients with SLE, along with clinical and laboratory 
      parameters.
CI  - Copyright (c) 2022 Lindblom, Zetterberg, Emamikia, Borg, von Perner, Enman, Heintz, 
      Regardt, Grannas, Gomez and Parodis.
FAU - Lindblom, Julius
AU  - Lindblom J
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Zetterberg, Sture
AU  - Zetterberg S
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Emamikia, Sharzad
AU  - Emamikia S
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Borg, Alexander
AU  - Borg A
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - von Perner, Gunilla
AU  - von Perner G
AD  - Swedish Rheumatism Association, Stockholm, Sweden.
FAU - Enman, Yvonne
AU  - Enman Y
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Heintz, Emelie
AU  - Heintz E
AD  - Department of Learning, Informatics, Management and Ethics (LIME), Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Regardt, Malin
AU  - Regardt M
AD  - Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 
      Stockholm, Sweden.
AD  - Medical Unit Occupational Therapy and Physiotherapy, Karolinska University 
      Hospital, Stockholm, Sweden.
FAU - Grannas, David
AU  - Grannas D
AD  - Division of Biostatistics, Institute of Environmental Medicine, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Gomez, Alvaro
AU  - Gomez A
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Parodis, Ioannis
AU  - Parodis I
AD  - Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, 
      Karolinska University Hospital, Stockholm, Sweden.
AD  - Department of Rheumatology, Faculty of Medicine and Health, Orebro University, 
      Orebro, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20221220
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC9807754
OTO - NOTNLM
OT  - health-related quality of life
OT  - organ damage
OT  - outcomes research
OT  - patient perspective
OT  - patient-reported outcomes
OT  - systemic lupus erythematosus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/07 06:00
MHDA- 2023/01/07 06:01
PMCR- 2022/12/20
CRDT- 2023/01/06 02:46
PHST- 2022/11/07 00:00 [received]
PHST- 2022/12/02 00:00 [accepted]
PHST- 2023/01/06 02:46 [entrez]
PHST- 2023/01/07 06:00 [pubmed]
PHST- 2023/01/07 06:01 [medline]
PHST- 2022/12/20 00:00 [pmc-release]
AID - 10.3389/fmed.2022.1092325 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Dec 20;9:1092325. doi: 10.3389/fmed.2022.1092325. 
      eCollection 2022.